Dr. Sehgal is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5115 Centre Ave
Upmc Cancer Pavillion. 5th Floor
Pittsburgh, PA 15232Phone+1 412-692-4724
Education & Training
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2010 - 2013- University of Pennsylvania Health SystemResidency, Internal Medicine, 2007 - 2010
Duke University School of MedicineClass of 2007
Certifications & Licensure
PA State Medical License 2007 - 2024- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) Start of enrollment: 2011 Oct 01
- Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2013 Dec 09
- Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2014 Feb 20
- Join now to see all
Publications & Presentations
PubMed
- 37 citationsDNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies.A P Im, A R Sehgal, M P Carroll, B D Smith, A Tefferi
Leukemia. 2014-09-01 - 23 citationsTwo-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001.Jeremy S Abramson, M Lia Palomba, Leo I Gordon, Matthew Lunning, Michael Wang
Blood. 2024-02-01 - 265 citationsAxicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.Caron A Jacobson, Julio C Chavez, Alison R Sehgal, Basem M William, Javier Munoz
The Lancet. Oncology. 2022-01-01
Abstracts/Posters
- Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cel...Alison R. Sehgal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymph...Alison R. Sehgal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in Three Ongoing Clinical Studies in Relapsed/Refractory (R/R) B Cell Non-Hodgkin Lymphoma (NHL), Includi...Alison R. Sehgal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- Lisocabtagene Maraleucel (liso-cel) for Treatment of Second-Line Transplant Noneligible (TNE) Relapsed/Refractory (R/R) Aggressive Non-Hodgkin Lymphoma (NHL): Initial ...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World ExperienceClinically Re...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Leukemia Cure Raises Hope for More PatientsFebruary 13th, 2022- New Graft Strategy May Improve Outcomes for Blood Stem Cell RecipientsJanuary 10th, 2022
- UPMC Partners with Be the Match, Stem Cell RegistryJuly 28th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
